Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will present a poster at the American Heart Association Scientific Sessions 2025 in New Orleans on November 10, 2025. The poster reports combined data on the efficacy, safety, and test-dose tolerability of self-administered etripamil for acute paroxysmal supraventricular tachycardia (PSVT) across multiple clinical trials.
The presentation is by James Ip, M.D. and is scheduled for Monday, November 10, 2025, 10:30–11:30 AM CST. The data describe patient-administered use of etripamil focusing on acute PSVT episodes.
Positive
- None.
Negative
- None.
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia.
AHA 2025 Presentation Details:
| Poster Presentation Title: | Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials |
| Presenter: | James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital |
| Date and time: | Monday, November 10, 2025, 10:30 – 11:30 AM CST |
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When will Milestone (MIST) present etripamil data at AHA 2025?
What topic will Milestone's AHA 2025 poster on MIST cover?
Who is presenting Milestone's etripamil poster at AHA 2025?
Where and when is the American Heart Association Scientific Sessions 2025 event?
What patient population is described in Milestone's AHA 2025 poster for MIST?
